Jove
Visualize
Contact Us

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

3.2K
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogenic Mutations in the Tumor Microenvironment Drive Tumor Progression in Diffuse Large B-Cell Lymphoma Through Tumor-Stroma Cross-Talk.

Cancers·2026
Same author

Inhibitory receptor agonists: Emerging strategies in immune modulation.

The Journal of experimental medicine·2026
Same author

Regulatory T cells in the tumour microenvironment.

Nature reviews. Cancer·2025
Same author

Multiplex targeting of immune-modulating genes in cancer.

Nature immunology·2025
Same author

Regulatory T cells in the tumor microenvironment display a unique chromatin accessibility profile.

ImmunoHorizons·2025
Same author

Tim-3 Is Required for Regulatory T Cell-Mediated Promotion of T Cell Exhaustion and Viral Persistence during Chronic Lymphocytic Choriomeningitis Virus Infection.

Journal of immunology (Baltimore, Md. : 1950)·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

433

LAG-3 as the third checkpoint inhibitor.

Vaishali Aggarwal1,2, Creg J Workman1,2, Dario A A Vignali3,4,5

  • 1Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Nature Immunology
|July 24, 2023
PubMed
Summary
This summary is machine-generated.

Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor on exhausted T cells. This perspective explores current debates and knowledge gaps in LAG-3 biology and its therapeutic potential.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Related Experiment Videos

Last Updated: Jul 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

433
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Area of Science:

  • Immunology
  • Cancer Immunotherapy
  • Molecular Biology

Background:

  • Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor predominantly found on exhausted T cells.
  • LAG-3 is a significant target in immunotherapy, with numerous therapeutics in clinical trials and an approved combination therapy for melanoma.
  • Despite its recognized inhibitory role, critical aspects of LAG-3's biology and function require further elucidation.

Purpose of the Study:

  • To address the existing knowledge gaps in Lymphocyte activation gene 3 (LAG-3) biology.
  • To highlight key areas of ongoing debate and research focus concerning LAG-3.
  • To provide a comprehensive overview of LAG-3's role in disease and therapeutic development.

Main Methods:

  • This perspective synthesizes current research and clinical findings.
  • It focuses on identifying and discussing major unresolved questions in the field.
  • The review covers ligands, signaling pathways, cellular functions, disease relevance, and therapeutic strategies.

Main Results:

  • Several critical questions persist regarding LAG-3's ligands and their interactions.
  • The precise signaling pathways and mechanisms of action for LAG-3 are still under investigation.
  • Understanding cell-specific functions and disease-specific roles of LAG-3 is crucial for effective targeting.

Conclusions:

  • LAG-3 represents a vital target for novel immunotherapeutic strategies.
  • Further research into LAG-3 biology is essential for optimizing its clinical application.
  • Addressing current debates will accelerate the development of more effective cancer treatments.